Novel compounds to combat trypanosomatid infections: A medicinal chemical perspective

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 5, 2011, Pages 699-715

  González, Mercedes ^a,b   Cerecetto, Hugo ^a,b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

American trypanosomiasis; human African trypanosomiasis; leishmaniasis; trypanosomatid infections

Indexed keywords

14 HYDROXYLUNULARIN; 1H BENZO[F ]INDAZOLE 4,9 DIONE; 2,2' BIFURAN DERIVATIVE; 2H BENZO[F ]INDAZOLE 4,9 DIONE; ANTILEISHMANIAL AGENT; ANTITRYPANOSOMAL AGENT; DICATIONIC DIARYL DERIVATIVE; DINITROBENZENE DERIVATIVE; ETHENYLBENZOFUROXAN DERIVATIVE; INDAZOLE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; TETRAHYDROFURO[3,2 B]PYRROL 3 ONE DERIVATIVE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FUNGAL STRAIN; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; REVIEW; TRYPANOSOMATID INFECTION;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 79955116867     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.565334     Document Type: Review

References (74)

1. Podlipaev S. The more insect trypanosomatids under study-the more diverse Trypanosomatidae appears. Int J Parasitol 2001;31:648-52 (Pubitemid 32382071)
2. Available from: svc/diseases/african-trypanosomiasis [Last accessed 10 October 2010]
3. Available from: . int/tdr/svc/diseases/chagas [Last accessed 10 October 2010]
4. Available from: . int/tdr/svc/diseases/leishmaniasis [Last accessed 10 October 2010]
5. Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst Rev 2010;8:CD006201
6. Cerecetto H, Gonzalez M. Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of "Hit-to-Lead" phase. Pharmaceuticals 2010;3:810-38
7. van Griensven J, Balasegaram M, Meheus F, et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010;10:184-94
8. Boykin DW, Tidwell RS, Wilson WD, et al. Dicationic triaryl analogs as anti-protozoan agents. WO2005040132; 2005
9. Boykin DW, Tidwell RS, Wilson WD, et al. Novel dicationic imidazo[1,2-a] pyridines and 5,6,7,8-tetrahydro-imidazo [1,2-a]pyridines as antiprotozoal agents. WO2005086808; 2005
10. Athri P, Wenzler T, Ruiz P, et al. 3D QSAR on a library of heterocyclic diamidine derivatives with antiparasitic activity. Bioorg Med Chem 2006;14:3144-52
11. Mathis AM, Bridges AS, Ismail MA, et al. Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and dristribution in trypanosomes. Antimicrob Agents Chemother 2007;51:2801-10 (Pubitemid 47206215)
12. Rahimian M, Kumar A, Say M, et al. Minor groove binding compounds that jump a GC base pair and bind to adjacent AT base pair sites. Biochemistry 2009;48:1573-83
13. Wang MZ, Zhu X, Srivastava A, et al. Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2010;54:2507-16
14. Huang TL, Vanden Eynde J-J, Mayence A, et al. Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis. WO2008070831; 2008
15. Windsor WT, Weber PC, Strickland C, et al. Treatment of Trypanosoma brucei with farnesyl protein transferase inhibitors. US20030134846A1; 2003
16. Pays E, Vanhamme L, Paturiaux-Hanocq F, et al. Apolipoprotein L-1 and/or derivated polypeptide for the treatment and/or the prevention of diseases induced by trypanosoma. US2006263348; 2006
17. Yamamoto M, Kodama H. Composition for preventing infection of protozoan, and method for preventing infection. JP2008195668; 2008
18. Haberkorn A, Elbe H-L, Buechel K-H. Use of substituted hydroxyalkylazoles for the treatment of Chagas' disease. DE3542676; 1987
19. Quibell M. Inhibitors of cruzipain and other cysteine proteases. NZ526913; 2004
20. Cazzulo JJ. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of chagas disease. Curr Top Med Chem 2002;2:1261-71
21. Ellman JA, Brak K. Nonpeptidic inhibitors of cruzain. WO2009075778; 2009
22. Paez Prosper JA, Campillo Martin NE, Guerra Alvarez A, et al. New family of antichagasics derived from imidazo[4,5-c]
23. [1,2,6]thiadiazine 2,2-dioxide. ES2343348; 2010
24. Cerecetto H, Di Maio R, Gonzalez M, et al. Derivados de 5-etenilbenzofuroxano, procedimiento de preparacion y utilizacion. UY20030028019; 2005
25. Porcal W, Merlino A, Boiani M, et al. Arylethenylbenzofuroxan derivatives as drugs for Chagas disease: multigram batch synthesis using a Wittig-Boden process. Org Proc Res Dev 2008;12:156-62
26. Gerpe A, Merlino A, Boiani M, et al. Development of a HPLC method for the determination of antichagasic phenylethenylbenzofuroxans and its major synthetic secondary products in the chemical production processes. J Pharm Biomed Anal 2008;47:88-94
27. Boiani L, Davies C, Arredondo C, et al. In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas disease. Eur J Med Chem 2008;43:2229-37
28. Boiani M, Merlino A, Gerpe A, et al. o-Nitroanilines as major metabolic products of anti-T. cruzi 5-phenylethenylbenzofuroxans in microsomal and cytosolic fractions of rat hepatocytes and in whole parasitic cells. Xenobiotica 2009;39:236-48
29. Cabrera M, Lavaggi ML, Hernandez P, et al. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol Lett 2009;190:140-9
30. Terra Martins F, Ayala A, Porcal W, et al. Structural relationships in the solid state of the anti-Chagas agent (E)-phenylethenylbenzofuroxan. Mol Divers 2009; doi:10.1007/ s11030-009-9202-4
31. Gambino D, Cerecetto H, Otero L, et al. Complejos metalicos de paladio y platino con tiosemicarbazonas derivadas de 5-nitrofurano, procedimiento de preparacion y utilizacion. UY20040028563; 2006
32. Otero L, Vieites M, Boiani L, et al. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolismo as potencial therapeutic targets. J Med Chem 2006;49:3322-31 (Pubitemid 43830530)
33. Franco DW, Santana da Silva J, Nogueira da Silva JJ. Processo de obtencao de um composto transportador de benznidazol a base de rutenio, composto transportador de benznidazol a base de rutenio e uso do compostotransportador de benznidazol a base de rutenio. BRPI0704577; 2009
34. Nogueira Silva JJ, Pavanelli WR, Salazar Gutierrez FR, et al. Complexation of the anti-Trypanosoma cruzi drug Benznidazole improves solubility and efficacy. J Med Chem 2008;51:4104-14 (Pubitemid 352032438)
35. Miyata Y, Sakaguchi S, Suzuki T, et al. Antiprotozoal agent. JP4356419; 1992
36. Paranhos-Baccala G, Lesenechal M, Jolivet M, et al. Trypanosoma cruzi antigen, gene encoding therefore, and methods of detecting and treating Chagas disease. WO09929867; 1999
37. Skeiky YAW. Compounds and methods for the detection and prevention of T. cruzi. MXPA01008621; 2002
38. Roldos V, Pandolfi E, Nakayama H, et al. Proceso de preparacion de 14-hidroxilunularina e intermediaries para el tratamiento contra la Leishmaniasis. UY20020027607; 2003
39. Roldos V, Nakayama H, Rolon M. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem 2008;43:1797-807
40. Ouaissi A, Sereno D, Vergnes B. Pharmaceutical compositions for the treatment of Leishmaniasis. WO2006008082; 2006
41. Yli-Kauhaluoma J, Alakurtti S, Minkkinen J, et al. Betulin derived compounds useful as antiprotozoal agents. WO2007141391; 2007
42. Guay D, Beaulieu C, Percival MD. Therapeutic utility and medicinal chemistry of cathepsin C inhibitors. Curr Top Med Chem 2010;10:708-16
43. Jeong JU, Yamashita DS. Protease inhibitors. WO2003104257; 2003
44. Jeong JU, Yamashita DS. Protease inhibitors. WO2005034838; 2005
45. Burke PJ, Melton R, Knox RJ. Method of combating infection. WO2007026166; 2007
46. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).Cancer Metastasis Rev 1993;12:195-212 (Pubitemid 23220681)
47. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-aziridin-1-yl)-2,4- dinitrobenzamide).Biochem Pharmacol 1991;41:867-75
48. Tidwell RR, Werbovetz K, Franzblau SG, et al. Cationic substituted benzofurans as antimicrobial agents. WO2005055935; 2005
49. Sas B, Van Hemel J, Vandenkerckhove J, et al. Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites. WO2004062590; 2004
50. Werbovetz K, Bhattacharya G, Sackett D, et al. Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin. WO2003090678; 2003
51. Werbovetz K, Brun R, Tidwell RR, et al. 5,5¢-Bis-(4-amidinophenyl)- 2,2¢-bifuran derivatives and related compounds as antiprotozoal agent and prodrugs thereof. EP1726589; 2006
52. Brun R, Werbovetz K, Tidwell RR, et al. 2,5-Diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents. WO2009051796; 2009
53. Ahlem CN, Frincke JM, Prendergast PT. 17-Ketosteroid compounds. KR20070004149; 2007
54. Hiroyuki S, Yoshihiro S, Kiyoshi K, et al. Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient. US7622598B2; 2009
55. Masataka I, Kiyosei T, Khanitha P, et al. Anti-trypanosomiasis agent. US7795285B2; 2010
56. Kayser O, Laatsch H, Kiderlen AF. Use of N2-substituted benz[f]indazole- 4,9-quinones as antiparasitic agents. WO0180838; 2001
57. Kayser O, Laatsch H, Kiderlen AF. Use of naphthindazole-4,9-quinones as antiparasitic agents. WO0180839; 2001
58. Ferreira ME, Fournet A, Rojas de Arias A, et al. Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases. WO2004050092; 2004
59. Fakhfakh M, Figadere B, Fournet A, et al. Substituted quinolines for the treatment of protozoa and retrovirus co-infections. US20050165052; 2005
60. Gantier JC, Fournet A, Munos MH, et al. The effect of some 2-substituted quinolines isolated from Galipea longiflora on Plasmodium vinckei petteri infected mice. Planta Med 1996;62:285-6 (Pubitemid 26201435)
61. Srebnik M, Takrouri K, Shalom E. Novel amine-borane compounds and uses thereof. WO2007032005; 2007
62. Jiricek J, Patel S, Keller TH, et al. Nitroimidazole compounds. WO2007075872; 2007
63. Ang SH, Krastel P, Leong SY, et al. Organic compounds. US20090275560A1; 2009
64. Brand S, Wyatt P. N-Myristoyl transferase inhibitors. WO2010026365A1; 2010
65. Zhou H, Ding D, Feng Y, et al. Boron-containing small molecules as anti-protozoal agents. WO2010045505A1; 2010
66. Baker SJ, Akama T, Bellinger-Kawahara C, et al. Boron-containing small molecules. US2006234981; 2006
67. Strauss PR. Identification of therapeutic agents effective against infection by members of the parasite family trypanosomatidae. WO199428162; 1994
68. Minoprio P, Alzari P, Buschiazzo A, et al. Crystallographic structure of Tcpraca and uses therefor. US2008113422; 2008
69. El-Sayed NM, Myler PJ, Bartholomeu DC, et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 2005;309:404-9
70. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008;105:5022-7 (Pubitemid 351738503)
71. Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 2009;11:e31
72. Arafa RK, Ismail MA, Munde M, et al. Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents. Eur J Med Chem 2008;43:2901-8
73. Chondrogianni N, Gonos ES. Proteasome function determines cellular homeostasis and the rate of aging. Adv Exp Med Biol 2010;694:38-46
74. Marquis RW, Ru Y, Veber DF, et al. Protease inhibitors. WO200195911A1; 2001